Literature DB >> 12074407

p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.

Andrés Rodríguez-Alonso1, Salvador Pita-Fernández, Joaquín González-Carreró, José Luis Nogueira-March.   

Abstract

OBJECTIVE: To determine prognostic factors for survival in bladder transitional cell carcinoma (TCC), and the prognostic value of p53 and ki67.
MATERIAL AND METHODS: A study was made of patients with stage T1 primary bladder TCC (n = 175). The immunohistochemical study was carried out using DO7 and MIB-1 monoclonal antibodies, for p53 and ki67, respectively. Kaplan-Meier methodology was used for the survival analysis, and the log-rank test was applied in order to determine accumulated probability rates of survival. Moreover, Cox's multivariate regression analysis was also used to establish the variables associated with survival. Receiver operating characteristic (ROC) curves were also drawn, with the aim of determining the prognostic capacity of p53 and ki67.
RESULTS: The average follow-up period was 7.3 years. Cancer-related survival rates at 5 and 10 years were 89.51 and 80.68%, respectively. The increase in p53 and ki67 expressions paralleled the histological grade, both markers showing significant inter-group differences (P = 0.0000). The variables which modified cancer-related survival significantly in the univariate analysis were the following: tumour multifocality, solid microscopic morphology, large cell nucleus and a high expression of p53 and ki67. Independent cancer-related survival variables were: age, tumour size of >3 cm, a solid microscopic growth pattern and expression of p53.
CONCLUSIONS: The expression of p53, increase in age, tumour size of >3 cm and microscopic growth pattern are independent predictors for cancer-related survival. A positive correlation was observed, indicating that, the higher the expression of p53, the greater the probability of death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074407     DOI: 10.1016/s0302-2838(01)00038-0

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  12 in total

Review 1.  Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas.

Authors:  Christopher Y Thomas; Dan Theodorescu
Journal:  World J Urol       Date:  2006-11       Impact factor: 4.226

2.  Cripto-1 expression and its prognostic value in human bladder cancer patients.

Authors:  Bingbing Wei; Wei Jin; Jun Ruan; Zhuoqun Xu; You Zhou; Jiabei Liang; Huan Cheng; Ke Jin; Xing Huang; Peng Lu; Qiang Hu
Journal:  Tumour Biol       Date:  2014-10-19

3.  Prediction of the postoperative prognosis in patients with non-muscle-invasive bladder cancer based on preoperative serum surface-enhanced Raman spectroscopy.

Authors:  Ruochen Zhu; Yuanjun Jiang; Zheng Zhou; Shanshan Zhu; Zhuoyu Zhang; Zhilin Chen; Shuo Chen; Zhe Zhang
Journal:  Biomed Opt Express       Date:  2022-07-11       Impact factor: 3.562

4.  Evaluation of relationship between HIF-1alpha immunoreactivity and stage, grade, angiogenic profile and proliferative index in bladder urothelial carcinomas.

Authors:  Hale Deniz; Metin Karakök; Faruk Yagci; Muhammet Emin Güldür
Journal:  Int Urol Nephrol       Date:  2009-05-30       Impact factor: 2.370

5.  ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

Authors:  Johannes Breyer; Ralph M Wirtz; Mark Laible; Kornelia Schlombs; Philipp Erben; Maximilian Christian Kriegmair; Robert Stoehr; Sebastian Eidt; Stefan Denzinger; Maximilian Burger; Arndt Hartmann; Wolfgang Otto
Journal:  Virchows Arch       Date:  2016-08-11       Impact factor: 4.064

6.  Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin.

Authors:  Sultan S Alkhateeb; Mischel Neill; Sas Bar-Moshe; Bas Van Rhijn; David M Kakiashvili; Neil Fleshner; Michael Jewett; Michel Petein; Claude Schulman; Sally Hanna; Peter J Bostrom; Thierry Roumeguere; Shahrokh F Shariat; Sandrine Rorive; Alexandre R Zlotta
Journal:  Urol Ann       Date:  2011-09

7.  Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder.

Authors:  Malte W Vetterlein; Julia Roschinski; Philipp Gild; Phillip Marks; Armin Soave; Ousman Doh; Hendrik Isbarn; Wolfgang Höppner; Walter Wagner; Shahrokh F Shariat; Maurizio Brausi; Franziska Büscheck; Guido Sauter; Margit Fisch; Michael Rink
Journal:  Transl Androl Urol       Date:  2017-12

8.  Diagnostic algorithm for papillary urothelial tumors in the urinary bladder.

Authors:  Jung-Weon Shim; Kang Su Cho; Young-Deuk Choi; Yong-Wook Park; Dong-Wha Lee; Woon-Sup Han; Sang-In Shim; Hyun-Jung Kim; Nam Hoon Cho
Journal:  Virchows Arch       Date:  2008-03-01       Impact factor: 4.064

9.  Chemoprevention of rat liver toxicity and carcinogenesis by Spirulina.

Authors:  Mohamed F Ismail; Doaa A Ali; Augusta Fernando; Mohamed E Abdraboh; Rajiv L Gaur; Wael M Ibrahim; Madhwa H G Raj; Allal Ouhtit
Journal:  Int J Biol Sci       Date:  2009-06-02       Impact factor: 6.580

10.  Role of morphometry and proliferative parameters in grading of urothelial neoplasms.

Authors:  Monika Sangwan; Sunita Singh; Santosh Kumar; Sonia Chabbra; Rajeev Sen; Praveen Rana; Shivani Malik; Sonia Singh; Ramesh Lamba
Journal:  Cent European J Urol       Date:  2015-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.